These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 24432249)

  • 1. Effects of RANKL-Targeted Therapy in Immunity and Cancer.
    Cheng ML; Fong L
    Front Oncol; 2014 Jan; 3():329. PubMed ID: 24432249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of the RANKL-RANK Axis in Immunity-Implications for Pathogenesis and Treatment of Bone Metastasis.
    Li B; Wang P; Jiao J; Wei H; Xu W; Zhou P
    Front Immunol; 2022; 13():824117. PubMed ID: 35386705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
    de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
    Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do RANKL inhibitors (denosumab) affect inflammation and immunity?
    Ferrari-Lacraz S; Ferrari S
    Osteoporos Int; 2011 Feb; 22(2):435-46. PubMed ID: 20571772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-RANKL antibody].
    Omiya T; Tanaka S
    Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of denosumab for the treatment of osteoporosis.
    Miyazaki T; Tokimura F; Tanaka S
    Patient Prefer Adherence; 2014; 8():463-71. PubMed ID: 24748775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
    Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
    Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal and extraskeletal actions of denosumab.
    Sinningen K; Tsourdi E; Rauner M; Rachner TD; Hamann C; Hofbauer LC
    Endocrine; 2012 Aug; 42(1):52-62. PubMed ID: 22581255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
    Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
    J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy.
    Ahern E; Smyth MJ; Dougall WC; Teng MWL
    Nat Rev Clin Oncol; 2018 Nov; 15(11):676-693. PubMed ID: 30232468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the RANK/RANKL pathway in breast cancer.
    Kiesel L; Kohl A
    Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
    De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
    Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab: A comprehensive review.
    Narayanan P
    South Asian J Cancer; 2013 Oct; 2(4):272-7. PubMed ID: 24455656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The RANKL-RANK Axis: A Bone to Thymus Round Trip.
    Sobacchi C; Menale C; Villa A
    Front Immunol; 2019; 10():629. PubMed ID: 30984193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab: a new option in the treatment of bone metastases from urological cancers.
    Yuasa T; Yamamoto S; Urakami S; Fukui I; Yonese J
    Onco Targets Ther; 2012; 5():221-9. PubMed ID: 23055747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.
    van Dam PA; Verhoeven Y; Trinh XB; Wouters A; Lardon F; Prenen H; Smits E; Baldewijns M; Lammens M
    Crit Rev Oncol Hematol; 2019 Jan; 133():85-91. PubMed ID: 30661662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab for the treatment of bone metastases in advanced breast cancer.
    Casas A; Llombart A; Martín M
    Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
    Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
    Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANK and RANK ligand expression in primary human osteosarcoma.
    Branstetter D; Rohrbach K; Huang LY; Soriano R; Tometsko M; Blake M; Jacob AP; Dougall WC
    J Bone Oncol; 2015 Sep; 4(3):59-68. PubMed ID: 27556008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
    Mera K; Ito K
    Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.